WO2003031468A1 - Molecules therapeutiques et diagnostiques pouvant interagir avec des proteines socs - Google Patents

Molecules therapeutiques et diagnostiques pouvant interagir avec des proteines socs Download PDF

Info

Publication number
WO2003031468A1
WO2003031468A1 PCT/AU2002/001353 AU0201353W WO03031468A1 WO 2003031468 A1 WO2003031468 A1 WO 2003031468A1 AU 0201353 W AU0201353 W AU 0201353W WO 03031468 A1 WO03031468 A1 WO 03031468A1
Authority
WO
WIPO (PCT)
Prior art keywords
socs
molecule
animal
igf
cell
Prior art date
Application number
PCT/AU2002/001353
Other languages
English (en)
Inventor
Douglas James Hilton
Nicos A. Nicola
Warren Scott Alexander
Robyn Starr
Sandra Elaine Nicholson
Tracy Willson
Elizabeth Viney
Steven Rakar
Danielle Krebs
Manuel Baca
Rachel Uren
Original Assignee
The Walter And Eliza Hall Institute Of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Walter And Eliza Hall Institute Of Medical Research filed Critical The Walter And Eliza Hall Institute Of Medical Research
Publication of WO2003031468A1 publication Critical patent/WO2003031468A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Definitions

  • the present invention relates generally to molecules which are capable of interacting with members of the family of suppressors of cytokine signalling (SOCS) proteins.
  • SOCS cytokine signalling
  • the molecules range from intracellular proteinaceous targets for which the SOCS is a ligand to chemicals including proteinaceous entities identified inter alia by screening of natural products, chemical libraries and/or through rational drug design.
  • the identification of intracellular targets of a SOCS protein and/or the identification of other interactors of the SOCS molecule permits the development of a range of therapeutic and diagnostic applications.
  • the present invention particularly relates to SOCS-6 and its involvement in various physiological processes such as those mediated by growth factor or hormone signalling.
  • SOCS proteins contain aC-terminal homology domain which is termed the "SOCS box" [Starr, R., et al., Nature (London) 387: 917-921 1997].
  • the first member of this family was called CIS (cytokine-inducible SH2-containing protein) [Yoshimura, A. et al., EMBO J. 14: 2816-2826 1995] and was shown to inhibit erythropoietin and interleukin-3 receptor signalling.
  • SOCS-1 was cloned from a retro viral expression library as a cDNA whose constitutive expression inhibited interleukin-6-induced differentiation of Ml [Starr, R., et al, Nature (London) 387: 917-921 1997] cells and it was simultaneously cloned as a protein that interacted with activated JAK kinases (JAK-binding protein, JAB) [Endo, T.A., et al. Nature (London) 387: 921-924, 1997] and as a protein with antigenic similarity to STATs (STAT-inducible STAT inhibitor, SSI) [Naka, T., et al., Nature (London) 387: 924-929 1997].
  • JAK kinases JAK-binding protein, JAB
  • STAT-inducible STAT inhibitor, SSI STAT-inducible STAT inhibitor
  • JAKs receptor-associated cytoplasmic kinases
  • STATs signal transducers and activators of transcription
  • Phosphorylated STAT dimers translocate to the nucleus and activate transcription of specific genes including those of CIS and some of the SOCS.
  • SOCS proteins then recognize activated signalling molecules (including JAKs and cytokine receptors) through their SH2 and N-terminal domains and inhibit their activity [Narazaki, M., et al. Proc. Natl. Acad. Sci. USA 95: 13130-13134 1998]). Exactly how SOCS proteins inhibit JAK kinase activity and the role of the conserved SOCS box are currently unknown.
  • SOCS-6 is one member of the suppressor of cytokine signalling (SOCS) family of proteins and comprises the characteristic central SH2 domain and C-terminal SOCS box.
  • SOCS-6 cytokine signalling
  • a biochemical analysis of SOCS-6 has revealed that it is a ubiquitously expressed cytosolic protein.
  • SOCS-6 binds to elongins B and C. This suggests that SOCS-6 may act as an E3 ubiquitin ligase, targeting proteins which interact through its SH2 domain for ubiquitination and proteasomal degradation.
  • the inventors sought to identify molecules which interact with the SOCS-6 SH2 domain. Such molecules and in particular endogenous proteinaceous molecules enable elucidation of signalling pathways involving
  • SOCS-6 interacts with wter alia insulin receptor substrate-4, insulin receptor substrate-2 and the p85 regulatory subunit of P13K (p85 ⁇ and p85 ⁇ ) (IRS-4, IRS-2 and p85) and, hence, is involved in insulin-like growth factor (IGF) and insulin receptor (IR) signalling.
  • IGF insulin-like growth factor
  • IR insulin receptor
  • the SOCS-6 and related SOCS molecules are involved in suppression of IR signalling in the presence of insulin and/or
  • SEQ ID NO: Nucleotide and amino acid sequences are referred to by a sequence identifier number (SEQ ID NO:).
  • the SEQ ID NOs: correspond numerically to the sequence identifiers ⁇ 400>1, ⁇ 400>2, etc.
  • a sequence listing is provided after the bibliography.
  • the present invention is predicated in part on the surprising observation that SOCS-6 associates with tyrosine-phosphorylated proteins in response to IGF-1 stimulation. These proteins were identified to include inter alia IRS-4, IRS-2 and p85. It is proposed, in accordance with the present invention, that SOCS-6 interacts with IRS-4, IRS-2 and p85 before, during and/or after stimulation mediated by IGF and/or its isoforms or homologues and in particular IGF-1. The identification of SOCS-6's involvement in IGF-mediated signalling indicates that this molecule is involved in inhibition of ER signalling thereby contributing to cytokine or growth factor-mediated insulin resistance amongst other conditions.
  • the identification of the involvement of the SH2 domain of SOCS-6 provides a target for the identification of chemical and proteinaceous molecules capable of modulating SOCS-6 activity and, more particularly, their use as therapeutic agents in the treatment of insulin resistance, amongst other conditions such as those associated with IGF-mediated signalling.
  • one aspect of the present invention contemplates a method for modulating IGF-mediated and/or insulin-mediated signalling in an animal cell or in an animal comprising said cell, said method comprising administering to said cell or said animal comprising said cell an amount of an effector molecule capable of modulating the functional interaction between a SOCS molecule and insulin receptor or an insulin receptor substrate or a component in an IGF-mediated signalling pathway.
  • Another aspect of the present invention contemplates a method for modulating IGF-1- mediated and/or insulin-mediated signalling in an animal cell or in an animal comprising said cell, said method comprising administering to said cell or said animal comprising said cell an amount of an effector molecule capable of modulating the functional interaction between a SOCS molecule and insulin receptor or an insulin receptor substrate or a component in an IGF-1 -mediated signalling pathway.
  • a further aspect of the present invention provides a method for modulating IGF-1 and/or insulin-mediated signalling in an animal cell or in an animal comprising said cell, said method comprising administering to said cell or said animal comprising said cell an amount of an effector molecule capable of modulating the functional interaction between a SOCS molecule and insulin receptor or an insulin receptor substrate or a component in an IGF-1 -mediated signalling pathway.
  • Yet another aspect of the present invention contemplates' a method of ameliorating the effects of insulin resistance in an animal cell, said method comprising introducing to said animal cell or animal comprising said cell an antagonist of SOCS-6 for a time and under conditions sufficient to inhibit, reduce or otherwise suppress SOCS-6 inhibition of IGF-1- and/or insulin-mediated signalling pathways or a component in an IGF-1 mediated signalling pathway.
  • Still another aspect of the present invention contemplates a method of modulating activity of SOCS-6 in an animal such as a human, said method comprising administering to said human or mammal an effective amount of a molecule for a time and under conditions sufficient to inhibit SOCS-6 binding to an intracellular ligand such as IRS-2 or IRS-4.
  • Still yet another aspect of the present invention contemplates a method of modulating levels of SOCS-6 in a cell, said method comprising contacting a cell containing a SOCS gene with an effective amount of an inhibitor of expression of the SOCS-6 gene for a time and under conditions sufficient to modulate levels of said SOCS protein.
  • Even yet another aspect of the present invention contemplates a method of modulating signal transduction in a cell containing a SOCS-6 gene comprising contacting said cell with an effective amount of an inhibitor of SOCS-6 gene expression for a time sufficient to modulate levels of SOCS protein with the cell.
  • Another aspect of the present invention contemplates a method of modulating the activity of a cytokine or cytokine-like molecule, said method comprising administering to a subject a modulating effective amount of a molecule for a time and under conditions sufficient to decrease the biological activity of SOCS-6 or the suppressing effects of SOCS-6.
  • the molecule may be a proteinaceous molecule or a chemical entity and may also be a derivative of a polypeptide of the complex or its ligand.
  • a further aspect of the present invention contemplates a composition and in particular a pharmaceutical composition comprising an effector molecule as defined above and one or more pharmaceutically acceptable carriers and/or diluents.
  • Yet another aspect of the present invention further provides genetically modified animals in which one or both alleles of SOCS-6 are mutated alone or in combination with another mutation in one or both alleles for another gene such as encoding another SOCS molecule.
  • Still another aspect of the present invention provides a method of producing a genetically modified non-human animal, said method comprising introducing into embryonic stem cells of an animal a genetic construct comprising a SOCS-6 nucleotide sequence carrying a single or multiple nucleotide substitution, addition and/or deletion or inversion or insertion wherein there is sufficient SOCS-6 nucleotide sequences to promote homologous recombination with a SOCS-6 gene within the genome of said embryonic stem cells selecting for said homologous recombination and selecting embryonic stem cells which carry a mutated SOCS-6 gene and then generating a genetically modified animal from said embryonic stem cell.
  • Still another aspect of the present invention contemplates a method of screening for an effector molecule which is capable of modulating the functional interaction between a SOCS molecule and an intracellular ligand in an animal cell, said method comprising contacting in the presence of said intracellular ligand or analogue or derivative thereof a polypeptide comprising an SH2 domain of said SOCS molecule, or derivative of said SH2 domain, with a test agent; and detecting a reduced level of interaction between said ligand or analogue or derivative thereof and said SH2 domain or derivative relative to a reference level of said interaction in the absence of said test agent, wherein said reduced level is indicative of said agent being an effector molecule.
  • Figure la is a diagrammatic representation of the SOCS-6 molecule which identifies the region used for immunization to generate anti-SOCS-6 monoclonal antibodies.
  • Figure lb is a summary of the characteristics of the anti-SOCS-6 monoclonal antibodies.
  • Figure 2 is a diagrammatic representation showing the targeted disruption of the SOCS-6 gene by homologous recombination, (a) Genomic map of SOCS-6 gene; (b) Targeting vector; (c) Targeted allele.
  • Figure 3 is a photographic representation showing expression of SOCS-6 mRNA in tissues from wild-type (A and B) and SOCS-6 7" (B) mice.
  • Figure 4 is a photographic representation showing expression of SOCS-6 in tissues from wild-type and SOCS-6 " " mice,
  • Lysates were prepared from various organs taken from either wild-type (+/+) or SOCS-6 ⁇ '1' ⁇ (-/-) mice and immunoprecipitations were carried out using the ICI antiSOCS-6 mAb.
  • Western blotting was carried out using the 3A7 anti- SOCS-6 mAb.
  • This figure shows that an equal amount of protein was used for each immunoprecipitation. 40 ⁇ g of lysate from each sample was subjected to Western blotting using an anti-heat shock-70 pAb.
  • Figure 5 is a graphical representation showing that SOCS-6 " ⁇ mice are 10% smaller than wild-type littermates.
  • Figure 6 is a photographic and tabulated representation showing identification of proteins which associate with the SOCS-6 SH2 domain in response to IGF-1 stimulation.
  • 293T cells were stimulated with 200 ng/mL IGF-1, lysed and precipitated using the SOCS-6 SH2 domain (S6-SH2) or control resin. Precipitates were separated on a SDS-PAGE gel and stained with Coomassie blue. Bands of interest were excised and subjected to mass spectrometric analysis.
  • Figure 7 is a photographic representation showing that SOCS-6 associates with tyrosine- phosphorylated proteins in response to IGF-1 stimulation.
  • Figure 8 is a photographic representation showing that SOCS-6 associates with IRS-4 in response to stimulation with IGF-1.
  • 293T cells were left untransfected or were transiently transfected with either a FLAG epitope tagged version of SOCS-6 (S6) or a FLAG-tagged version of WSB-1.
  • Cells were left unstimulated (-) or were stimulated with 200 ng/mL IGF-1 (+).
  • FLAG-SOCS-6 and FLAG-WSB-1 were immunoprecipitated with anti-FLAG Abs.
  • non-transfected lysates were precipitated with the SOCS-6-SH2 domain, the SOCS-7-SH2 domain or control resin.
  • Western blotting was then carried out using an anti-IRS-4 Ab ( Figure 8a). The blot was stripped and reprobed using an anti- FLAG Ab ( Figure 8b).
  • Figure 9 is a photographic representation showing that SOCS-6 associates with p85 of PI 3 kinase in response to IGF-1 stimulation.
  • Figure 10 is a graphical representation showing a comparison of insulin production following glucose injection in wild-type and SOCS-6 " " mice.
  • Figure 11 is a graphical representation of the glucose tolerance test in wild-type and SOCS-6 " mice following glucose injection.
  • Figure 12 shows sequences of the degenerate libraries used to determine the sequences of preferred SOCS-6 and SOCS-7 phosphopeptide ligands.
  • Each X position is an equal mixture of 19 L-amino acids, with cysteine omitted to simplify the N-terminal sequencing analysis,
  • Figure 13 are graphical representations showing selection of phosphopeptides that bind the (a) SOCS-6 and (b) SOCS-7 SH2 domains.
  • the degenerate phosphopeptide mixtures ( Figure 12) were incubated with Sepharose resin containing either immobilized SOCS-6 or SOCS-7 SH2 domain.
  • the column was washed and bound peptides were eluted with 1% aqueous TFA.
  • the eluted peptide mixture was analyzed by N-terminal sequencing and the results compared to those from the eluate of Sepharose resin alone. Data is shown for the relative amino acid composition at each of the randomized positions within the libraries. The data has been normalized so that the sum of the values of all amino acids equals the number of amino acids (i.e. 19).
  • the present invention is predicated in part on the identification that SOCS-6 is involved in the IGF-1 -mediated signalling pathway and in the regulation of insulin production. It is proposed, in accordance with the present invention, that in the presence of IGF-1 and/or insulin, SOCS-6, induced by cytokines, associates with IRS-2, IRS-4, p85 and/or the ER thereby suppressing its function. This may contribute to, in conditions involving high cytokine involvement such as inflammation, acromegally and/or obesity, insulin resistance and development of diabetes such as type 2 diabetes.
  • the present invention provides a target, therefore, to identify therapeutic molecules capable of modulating expression of SOCS-6 and related SOCS molecules, or capable of modulating the interaction between SOCS-6 and related SOCS molecules and ERS-2, ER.S-4 and p85 for use in manipulating IGF-1 and insulin-mediated pathways.
  • one aspect of the present invention contemplates a method for modulating IGF-mediated and/or insulin-mediated signalling in an animal cell or in an animal comprising said cell, said method comprising administering to said cell or said animal comprising said cell an amount of an effector molecule capable of modulating the functional interaction between a SOCS molecule and insulin receptor or an insulin receptor substrate or a component in an IGF-mediated signalling pathway.
  • modulating means that the effector molecule may be an agonist or antagonist of SOCS interaction with its ligand.
  • An agonist would promote suppression of signalling mediated by the SOCS molecule.
  • An antagonist would inhibit suppression of signalling. Consequently, in conditions where IGF- and/or insulin-mediated signalling is down regulated such as in insulin resistance, then an antagonist is preferred. In conditions resulting in excess IGF- and/or insulin-mediated signalling, then an agonist is preferred.
  • IGF insulin growth factor
  • IGF-1 is the most preferred form of IGF.
  • another aspect of the present invention contemplates a method for modulating IGF-1 -mediated and/or insulin-mediated signalling in an animal cell or in an animal comprising said cell, said method comprising administering to said cell or said animal comprising said cell an amount of an effector molecule capable of modulating the functional interaction between a SOCS molecule and insulin receptor or an insulin receptor substrate or a component in an IGF-1 -mediated signalling pathway.
  • the present invention is particularly directed to SOCS-6 but extends to any SOCS molecule capable of interacting with and suppresses the function of the IGF- and/or insulin-mediated signalling pathways.
  • SOCS-6 is most preferred.
  • another aspect of the present invention provides a method for modulating IGF-1 and/or insulin-mediated signalling in an animal cell or in an animal comprising said cell, said method comprising administering to said cell or said animal comprising said cell an amount of an effector molecule capable of modulating the functional interaction between a SOCS-6 molecule and insulin receptor or an insulin receptor substrate or a component in an IGF-1 -mediated signalling pathway.
  • a “component" in the IGF-1- or insulin-mediated signalling pathways includes ERS-2,
  • another aspect of the present invention provides an effector molecule capable of modulating interaction between a SOCS molecule and an intracellular ligand in an animal cell wherein said effector molecule modulates IGF- and/or insulin-mediated signalling.
  • the effector molecule is an antagonist.
  • the antagonist interacts with the SH2 domain of the SOCS molecule.
  • the SOCS molecule is SOCS-6.
  • the effector molecule is capable of inhibiting SOCS-6 function and is useful in treating insulin resistance.
  • another aspect of the present invention is directed to a SOCS-6 antagonist wherein said antagonist inhibits SOCS-6-mediated suppression of IGF- and/or insulin- mediated signalling pathways.
  • the effector molecules of the present invention may be identified, for example, by screening a library of synthetic or natural agents.
  • Candidate agents encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 50 and less than about 2,500 Dalton.
  • Candidate agents typically comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups.
  • the candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups.
  • Candidate agents are also found among biomolecules including, but not limited to: peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogues or combinations thereof.
  • Small (non-peptide) molecule modulators of a SOCS molecule are particularly preferred.
  • small molecules are particularly preferred because such molecules are more readily absorbed after oral administration, have fewer potential antigenic determinants, and/or are more likely to cross the cell membrane than larger, protein-based pharmaceuticals.
  • Small organic molecules may also have the ability to gain entry into an appropriate cell and affect, for example, the interaction between the SOCS molecule and its intracellular ligand.
  • libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced.
  • the present invention contemplates "natural product screening” including screening environmental and biological locations such as coral, river beds, plants, microorganisms, rock formations, Antarctic or Arctic regions or sea water or sea beds for chemical molecules which are capable of interacting with a target SOCS molecule thereby modulating its function.
  • natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries.
  • Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterif ⁇ cation, amidification, etc. to produce structural analogues.
  • Screening may also be directed to known pharmacologically active compounds and chemical analogues thereof.
  • the effector molecule is capable of interacting with the SH2 domain of a SOCS molecule.
  • the effector molecule is an antagonist of said SOCS molecule.
  • the effector molecule comprises a phosphopeptide sequence.
  • the phosphopeptide sequence is preferably selected from:
  • pY is phosphotyrosine
  • Xi is Y, M, V, W, F or I, preferably V
  • X 2 is Y, M, V, W, F, I or L, preferably Y;
  • X 3 is M, V, W, F, I or L, preferably M, V, F or I; X is any amino acid, suitably N or W; and X 5 is any amino acid, suitably W.
  • the phosphopeptide sequence is preferably selected from:-
  • pY is phosphotyrosine
  • Xi is M, V, W, I or L, preferably V;
  • X 2 is any amino acid, suitably Q, T, E, Y, M, V, W, F, I or L;
  • X 3 is Y, M, W, F, I or L, preferably W or F;
  • X is any amino acid, suitably D, T, Y, V, W, or F;
  • X 5 is any amino acid, suitably D, H, Y, P, W, or F.
  • the invention encompasses any effector molecules which are capable of modulating the interaction between the SH2 domain of a SOCS molecule and its intracellular ligand.
  • another aspect of the present invention contemplates a method of screening for an effector molecule which is capable of modulating the functional interaction between a SOCS molecule and an intracellular ligand in an animal cell, said method comprising contacting in the presence of said intracellular ligand or analogue or derivative thereof a polypeptide comprising an SH2 domain of said SOCS molecule, or derivative of said SH2 domain, with a test agent; and detecting a reduced level of interaction between said ligand or analogue or derivative thereof and said SH2 domain or derivative relative to a reference level of said interaction in the absence of said test agent, wherein said reduced level is indicative of said agent being an effector molecule.
  • the SOCS molecule is selected from SOCS-6 or SOCS-7.
  • the polypeptide, which is contacted with the test agent preferably comprises the sequence set forth in SEQ ED NO: 7 or SEQ ED NO:8.
  • the polypeptide comprises the sequence set forth in SEQ ED NO: 9 or SEQ ED NO: 10.
  • the SH2 domain is contacted with the test agent in the presence of a phosphopeptide sequence as broadly described above.
  • the effector molecules is useful in treating or otherwise ameliorating the symptoms of insulin resistance.
  • another aspect of the present invention contemplates a method of ameliorating the effects of insulin resistance in an animal cell, said method comprising introducing to said animal cell or animal comprising said cell an antagonist of SOCS-6 for a time and under conditions sufficient to inhibit, reduce or otherwise suppress SOCS-6 inhibition of IGF-1- and/or insulin-mediated signalling pathways or a component in an IGF-1 mediated signalling pathway.
  • Reference to an "animal” includes a human, primate, livestock animal (e.g. sheep, pig, horse, cow donkey), laboratory test animal (e.g. mouse, rat, guinea pig, rabbit, hamster) or companion animals (e.g. dog, cat).
  • livestock animal e.g. sheep, pig, horse, cow donkey
  • laboratory test animal e.g. mouse, rat, guinea pig, rabbit, hamster
  • companion animals e.g. dog, cat.
  • the target animal is a human.
  • the target may be a laboratory test animal such as a mouse or rat.
  • the effector molecule may be found following natural product screening or screening of chemical libraries or may be generated by preparing derivatives of analogues of SOCS (e.g. SOCS-6) itself or a SOCS ligand (e.g. ERS-2, ERS-4 or p85).
  • SOCS e.g. SOCS-6
  • SOCS ligand e.g. ERS-2, ERS-4 or p85
  • derivatives or its singular form “derivative” in relation to a SOCS molecule and in particular SOCS-6 includes parts, mutants, fragments and analogues as well as hybrid or fusion molecules and glycosylation variants of the SOCS.
  • Particularly useful derivatives comprise single or multiple amino acid substitutions, deletions and/or additions to the SOCS SH2 domain and/or the SOCS box amino acid sequence.
  • the derivatives act as antagonists but agonists are also contemplated by the present invention.
  • the present invention further extends to homologues of SOCS-6 which include the functionally or structurally related molecules from different animal species.
  • the present invention also encompasses analogues and mimetics.
  • Mimetics include a class of molecule generally but not necessarily having a non-amino acid structure and which functionally are capable of acting in an analogous or antagonistic manner to the protein for which it is a mimic, in this case, SOCS-6.
  • Mimetics may comprise a carbohydrate, aromatic ring, lipid or other complex chemical structure or may also be proteinaceous in composition.
  • the present invention further extends to a range of deletion mutants of SOCS and in particular SOCS-6 carrying deletions in the SH2 or the SOCS box.
  • Molecules are also contemplated by the present invention which encompasses only the carboxy terminal region or amino terminal region or fused to another peptide, polypeptide or protein.
  • the present invention contemplates agonists and antagonists of SOCS-6.
  • Antibodies are one example of an antagonist although are more useful in diagnostic applications or in the purification of SOCS peptides.
  • the present invention provides antagonists of SOCS-6.
  • Such antagonists may be used, for example, in the treatment or prophylaxis of cytokine mediated dysfunction such as autoimmunity, immune suppression or hyperactive immunity or other condition including but not limited to dysfunctions in the haemopoietic, endocrine, hepatic and neural systems.
  • Dysfunctions mediated by other signal transducing elements such as hormones or endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites are also contemplated by the present invention. They may also be useful in promoting degradation or inhibiting degradation.
  • antagonists of SOCS-6 are useful in ameliorating the symptoms or effects of insulin resistance.
  • Analogues of SOCS-6 especially those acting as antagonists contemplated herein include, but are not limited to, modification to side chains, incorporating of unnatural amino acids and/or their derivatives during peptide, polypeptide or protein synthesis and the use of crosslinkers and other methods which impose conformational constraints on the proteinaceous molecule or their analogues.
  • side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH 4 ; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with NaBH 4 .
  • modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH 4 ; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS);
  • the guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.
  • the carboxyl group may be modified by carbodiimide activation via O-acylisourea formation followed by subsequent derivitisation, for example, to a corresponding amide.
  • Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4- chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2- chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.
  • Tryptophan residues may be modified by, for example, oxidation with N- bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides.
  • Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.
  • Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate.
  • Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3- hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or D-isomers of amino acids.
  • a list of unnatural amino acid, contemplated herein is shown below:-
  • Non-conventional Code Non-conventional Code amino acid amino acid
  • D-N-methylaspartate Dnmasp N-(2,2-diphenylethyl)glycine Nbhm
  • D-N-methylcysteine Dnmcys N-(3 ,3 -diphenylpropyl)glycine Nbhe
  • peptides can be conformationally constrained by, for example, incorporation of C ⁇ and N ⁇ -methylamino acids, introduction of double bonds between C ⁇ and C ⁇ atoms of amino acids and the formation of cyclic peptides or analogues by introducing covalent bonds such as forming an amide bond between the N and C termini, between two side chains or between a side chain and the N or C terminus.
  • glycosylation variants from a completely unglycosylated molecule to a modified glycosylated molecule. Altered glycosylation patterns may result from expression of recombinant molecules in different host cells.
  • Another aspect of the present invention contemplates a method of modulating activity of SOCS-6 in an animal such as a human, said method comprising administering to said human or mammal an effective amount of a molecule for a time and under conditions sufficient to inhibit SOCS-6-mediated binding to an intracellular ligand such as ERS-2 or ERS-4.
  • Still a further aspect of the present invention contemplates a method of modulating levels of SOCS-6 in a cell, said method comprising contacting a cell containing a SOCS gene with an effective amount of an inhibitor of expression of the SOCS-6 gene for a time and under conditions sufficient to modulate levels of said SOCS protein.
  • Yet a further aspect of the present invention contemplates a method of modulating signal transduction in a cell containing a SOCS-6 gene comprising contacting said cell with an effective amount of an inhibitor of SOCS-6 gene expression for a time sufficient to modulate levels of SOCS protein with the cell.
  • Still a further aspect of the present invention contemplates a method of modulating the activity of a cytokine or cytokine-like molecule, said method comprising administering to a subject a modulating effective amount of a molecule for a time and under conditions sufficient to decrease the biological activity of SOCS-6 or the suppressing effects of SOCS-6.
  • the molecule may be a proteinaceous molecule or a chemical entity and may also be a derivative of a polypeptide of the complex or its ligand.
  • the present invention contemplates a composition and in particular a pharmaceutical composition comprising an effector molecule as defined above and one or more pharmaceutically acceptable carriers and/or diluents. These components are referred to as the "active ingredients”.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) and sterile powders for the extemporaneous preparation of sterile injectable solutions. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dilution medium comprising, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of superfactants.
  • microoganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thirmersol and the like.
  • isotinic agents for example, sugars or sodium chloride.
  • Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
  • the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile- filtered solution thereof.
  • the active ingredients When the active ingredients are suitably protected they may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsule, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet.
  • the active compound For oral therapeutic administration, the active compound may be incorporated with excipients and used in the form of ingestible tablets, baccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
  • Such compositions and preparations should contain at least 1% by weight of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 5 to about 80% of the weight of the unit.
  • compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about 0.1 ⁇ g and 2000 mg of active compound.
  • Altemative dosage amounts include from about 1 ⁇ g to about 1000 mg and from about 10 ⁇ g to about 500 mg.
  • the present invention also extends to forms suitable for topical application such as creams, lotions and gels as well as a range of "paints" which are applied to skin and through which the active ingredients are absorbed.
  • the complex or components thereof may be associated with penetration or the TAT protein of HIN.
  • Pharmaceutically acceptable barriers and/or diluents include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
  • the use of such media and agents for pharmaceutical active substances is well known in the art and except insofar as any conventional media or agent is incompatible with the active ingredient, their use in the therapeutic compositions is contemplated.
  • Supplementary active ingredients can also be incorporated into the compositions.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active material for the treatment of disease in living subjects having a diseased condition in which bodily health is impaired as herein disclosed in detail.
  • the principal active ingredient is compounded for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable barrier in dosage unit form as hereinbefore disclosed.
  • a unit dosage form can, for example, contain the principal active compound in amounts range from 0.5 ⁇ g to about 2000 mg. Expressed in proportions, the active compound is generally present in from about 0.5 ⁇ g to about 2000 mg/ml of carrier.
  • the dosages are determined by reference to the usual dose and manner of administration of the said ingredients. Dosages may also be expressed per body weight of the recipient. For example, from about 10 ng to about 1000 mg/kg body weight, from about 100 ng to about 500 mg/kg body weight and for about 1 ⁇ g to above 250 mg/kg body weight may be administered.
  • the pharmaceutical composition may also comprise genetic molecules such as a vector capable of transfecting target cells where the vector carries a nucleic acid molecule capable of modulating levels of polypeptides involved in the complex.
  • the vector may, for example, be a viral vector.
  • the present invention further provides an animal model useful for assessing potential agonists and antagonists of SOCS-6 function.
  • the present invention further provides genetically modified animals in which one or both alleles of SOCS-6 are mutated alone or in combination with another mutation in one or both alleles for another gene such as encoding another SOCS molecule.
  • the genetically modified animals are laboratory test animals such as murine species (e.g. mice, rats), rabbits, guinea pigs or hamsters, livestock animals such as sheep, pigs, horses or cows or non-human mammals such as primates.
  • the genetically modified animal is a murine species such as a mouse or rat.
  • the genetic modification is generally in the form of a mutation such as a single or multiple nucleotide substitution, deletion and/or addition or inversion or insertion. Generally, such a genetically modified animal is refened to as a "knock-out" animal.
  • a targeting DNA construct comprising a nucleotide sequence which is sufficiently homologous to a target sequence such a SOCS-6 to permit homologous recombination.
  • the SOCS-6 targeting sequence may be isogenic or non-isogenic to the target SOCS-6 sequence.
  • the targeting DNA construct generally comprises a selectable marker within the targeting sequence such that by homologous recombination, the target SOCS-6 gene is disrupted by an insertional mutation.
  • the targeting DNA construct is generally introduced into an embryonic stem cell or embryonic stem cell line.
  • a mutation may be introduced which induces a phenotypic change which may then be selected or detected.
  • another aspect of the present invention provides a method of producing a genetically modified non-human animal, said method comprising introducing into embryonic stem cells of an animal a genetic construct comprising a SOCS-6 nucleotide sequence carrying a single or multiple nucleotide substitution, addition and/or deletion or inversion or insertion wherein there is sufficient SOCS-6 nucleotide sequences to promote homologous recombination with a SOCS-6 gene within the genome of said embryonic stem cells selecting for said homologous recombination and selecting embryonic stem cells which carry a mutated SOCS-6 gene and then generating a genetically modified animal from said embryonic stem cell.
  • the genetically modified animal is a murine species such as a mouse or rat.
  • the SOCS-6 nucleotide sequence may be isogenic or non-isogenic to the SOCS-6 gene in the embryonic stem cell.
  • the term "isogenic" means that the SOCS-6 nucleotide sequence in the construct is derived from the same animal strain from which the embryonic stem cell has been derived or a strain exhibiting the same genotype.
  • the present invention further contemplates non-homologous-mediated integration of the target DNA sequence.
  • a range of selectable markers may be employed and reference may be made to U.S. Patent No. 5,789,215 for general methodologies. Breeding protocols may also be adopted to introduce mutations or other genetic modifications into SOCS-6.
  • an EMS or other mutagenized mouse is cross with a non-mutagenized mouse to produce a Gl generation. The Gl generation may then be crossed with an index strain to produce GEFI kindreds which are then screened phenotypically for mutation in SOCS-6.
  • Mutations in SOCS-6 may be dominant or recessive and mutations may be detected directly on SOCS-6 or by its effect on another gene or on its effect in alleviating the effects of a first mutation on another gene.
  • All genetically modified animals including knock-out mice carrying mutations in one or both SOCS-6 alleles alone or in combination with mutations in other genes.
  • the present invention further contemplates antibodies to SOCS-6.
  • monoclonal antibodies in an immunoassay is particularly preferred because of the ability to produce them in large quantities and the homogeneity of the product.
  • the preparation of hybridoma cell lines for monoclonal antibody production derived by fusing an immortal cell line and lymphocytes sensitized against the immunogenic preparation can be done by techniques which are well known to those who are skilled in the art. (See, for example, refs. 9,10,11).
  • Another aspect of the present invention contemplates a method for detecting SOCS-6 in a biological sample from a subject said method comprising contacting said biological sample with an antibody specific for SOCS-6 or its derivatives or homologues for a time and under conditions sufficient for an antibody-SOCS-6 complex to form, and then detecting said complex.
  • SOCS-6 may be accomplished in a number of ways such as by Western blotting and ELIS A procedures.
  • a wide range of immunoassay techniques are available as can be seen by reference to U.S. Patent Nos. 4,016,043, 4,424,279 and 4,018,653. These, of course, includes both single-site and two-site or "sandwich" assays of the non- competitive types, as well as in the traditional competitive binding assays. These assays also include direct binding of a labelled antibody to a target.
  • Sandwich assays are among the most useful and commonly used assays and are favoured for use in the present invention. A number of variations of the sandwich assay technique exist, and all are intended to be encompassed by the present invention. Briefly, in a typical forward assay, an unlabelled antibody is immobilized on a solid substrate and the sample to be tested brought into contact with the bound molecule. After a suitable period of incubation, for a period of time sufficient to allow formation of an antibody-antigen complex, a second antibody specific to the antigen, labelled with a reporter molecule capable of producing a detectable signal is then added and incubated, allowing time sufficient for the formation of another complex of antibody-antigen-labelled antibody.
  • the sample is one which might contain SOCS-6 including cell extract, tissue biopsy or possibly serum, saliva, mucosal secretions, lymph, tissue fluid and respiratory fluid.
  • the sample is, therefore, generally a biological sample comprising biological fluid but also extends to fermentation fluid and supernatant fluid such as from a cell culture.
  • a first antibody having specificity for the SOCS-6 or antigenic parts thereof is either covalently or passively bound to a solid surface.
  • the solid surface is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.
  • the solid supports may be in the form of tubes, beads, discs of microplates, or any other surface suitable for conducting an immunoassay.
  • the binding processes are well-known in the art and generally consist of cross-linking covalently binding or physically adsorbing, the polymer-antibody complex is washed in preparation for the test sample.
  • an aliquot of the sample to be tested is then added to the solid phase complex and incubated for a period of time sufficient (e.g. 2-40 minutes or overnight if more convenient) and under suitable conditions (e.g. from room temperature to about 37°C including 25°C) to allow binding of any subunit present in the antibody.
  • the antibody subunit solid phase is washed and dried and incubated with a second antibody specific for a portion of the hapten.
  • the second antibody is linked to a reporter molecule which is used to indicate the binding of the second antibody to the hapten.
  • An alternative method involves immobilizing the target molecules in the biological sample and then exposing the immobilized target to specific antibody which may or may not be labelled with a reporter molecule. Depending on the amount of target and the strength of the reporter molecule signal, a bound target may be detectable by direct labelling with the antibody.
  • a second labelled antibody specific to the first antibody is exposed to the target-first antibody complex to form a target-first antibody-second antibody tertiary complex.
  • the complex is detected by the signal emitted by the reporter molecule.
  • reporter molecule is meant a molecule which, by its chemical nature, provides an analytically identifiable signal which allows the detection of antigen-bound antibody. Detection may be either qualitative or quantitative.
  • reporter molecules in this type of assay are either enzymes, fluorophores or radionuclide containing molecules (i.e. radioisotopes) and chemiluminescent molecules.
  • an enzyme is conjugated to the second antibody, generally by means of glutaraldehyde or periodate.
  • glutaraldehyde or periodate As will be readily recognized, however, a wide variety of different conjugation techniques exist, which are readily available to the skilled artisan.
  • Commonly used enzymes include horseradish peroxidase, glucose oxidase, -galactosidase and alkaline phosphatase, amongst others.
  • the substrates to be used with the specific enzymes are generally chosen for the production, upon hydrolysis by the corresponding enzyme, of a detectable color change. Examples of suitable enzymes include alkaline phosphatase and peroxidase.
  • the enzyme-labelled antibody is added to the first antibody hapten complex, allowed to bind, and then the excess reagent is washed away. A solution containing the appropriate substrate is then added to the complex of antibody-antigen- antibody. The substrate will react with the enzyme linked to the second antibody, giving a qualitative visual signal, which may be further quantitated, usually spectrophotometrically, to give an indication of the amount of hapten which was present in the sample.
  • Reporter molecule also extends to use of cell agglutination or inhibition of agglutination such as red blood cells on latex beads, and the like.
  • fluorescent compounds such as fluorecein and rhodamine
  • fluorescent compounds may be chemically coupled to antibodies without altering their binding capacity.
  • the fluorochrome-labelled antibody When activated by illumination with light of a particular wavelength, the fluorochrome-labelled antibody adsorbs the light energy, inducing a state to excitability in the molecule, followed by emission of the light at a characteristic color visually detectable with a light microscope.
  • the fluorescent labelled antibody is allowed to bind to the first antibody- hapten complex. After washing off the unbound reagent, the remaining tertiary complex is then exposed to the light of the appropriate wavelength, the fluorescence observed indicates the presence of the hapten of interest.
  • Immunofluorescene and EIA techniques are both very well established in the art and are particularly preferred for the present method. However, other reporter molecules, such as radioisotope, chemiluminescent or bioluminescent molecules, may also be employed.
  • the ability to identify SOCS-6 immunologically permits diagnostic assays for SOCS-6 alone or in a complex with other molecules such as molecules involved in growth factor or hormone signalling.
  • Diagnostic assays may also involve immobilizing SOCS-6 and screening for molecules which interact with SOCS-6.
  • particular ligands may be immobilized to screen for SOCS-6.
  • the ability to quantitate SOCS-6 or its ligands or complexes thereof provides significant diagnostic and therapeutic value.
  • SOCS-6 quantitation may also be conducted at the genetic level where mRNA transcript levels may be determined for the SOCS-6 gene. Such genetic assays may also be conducted at the DNA level especially to identify polymorphisms of SOCS-6.
  • differential hybridization or differential priming is useful in distinguishing between polymorphisms of the SOCS-6 gene.
  • Single nucleotide polymorphism (SNP) technology may also be employed.
  • SOCS molecules are described in International Patent Application No. PCT/AU97/00729 [WO 98/20023].
  • the nucleotide and amino acid sequences of SOCS-6 are shown in SEQ ED NOS:l and 2, respectively.
  • mice were immunized with a GST-SOCS-6 N-terminal peptide, as defined in Figure 1A. This peptide is referred to as "SOCS-6 N(B)". Splenocytes from immunized mice were then fused with myeloma cells and hydridomas were selected. Hybridoma supernatant fluids were then screened by ELISA to detect monoclonal antibodies (mAbs) which recognized GST SOCS6 N(B) but not GST alone.
  • mAbs monoclonal antibodies
  • the mAbs identified were then characterized by isotype, Ippt, Western blot and epitope to which it binds (defined by amino acid residue sequence). The results are shown in Figure lb. Two antibodies, ICl and IC3, were directed to amino acids numbers 250-290 of SOCS6 and 3A7 was directed to amino acid residues 290-330.
  • the SOCS-6 gene was disrupted in mouse embryonic stem (ES) cells by homologous recombination of a targeting vector carrying a selectable marker.
  • the targeting vector is shown in Figure 2b
  • the genomic target is shown in Figure 2a
  • the resulting targeted allele is shown in Figure 2c.
  • Four ES cell clones were identified carrying the targeted allele.
  • SOCS-6 knock-out mice generated using these ES cells were shown to be genotypically SOCS-6 " (see Example 4 and Figure 3).
  • SOCS-6 mRNA The expression of SOCS-6 mRNA was determined in tissues from wild-type mice and from mice genotypically SOCS-6 7" . The results are shown in Figure 3.
  • Figure 3a eye, testes, bone shaft, large intestine, muscle, bladder, spleen, liver, lung, bone marrow, heart, kidney, brain, thymus and salivary gland tissue was tested using a coding region corresponding to SOCS-6.
  • SOCS-6 mRNA was identified as a 2.33 kb band.
  • SOCS-6 7" mice lack this band in heart, kidney, brain, thymus and salivary gland tissue.
  • Figure 4 shows the results of Western blot analysis using anti-SOCS-6 antibodies generated in Example 2 in wild-type and SOCS-6 7" mice.
  • lysates were prepared from various organs taken from either wild-type (+/+) or SOCS-& " ' (-/-) mice and immunoprecipitations were carried out using the ICl antiSOCS-6 mAb.
  • Western blotting was carried out using the 3A7 anti-SOCS-6 mAb.
  • Figure 4b shows that an equal amount of protein was used for each immunoprecipitation. 40 ⁇ g of lysate from each sample was subjected to Western blotting using an anti-heat shock-70 pAb.
  • SOCS-6 " mice are born in normal mendelian ratio and survived normally for at least six months. Male and female mice appeared fertile. The weight versus age of SOCS-6 ' " mice was determined and compared to wild-type mice. The results presented in Figure 5 show that SOCS-6 " " mice are approximately 10% smaller than wild-type littermates.
  • 293T cells were stimulated with 200 ng/mL IGF-1, lysed and precipitated using the SOCS- 6 SH2 domain (S6-SH2) or control resin. Precipitates were separated on an SDS-PAGE gel and stained with Coomassie blue. Bands of interest were excised and subjected to mass spectrometric analysis.
  • 293T cells were transiently transfected with a FLAG epitope tagged version of SOCS-6 on a FLAG-tagged version of WSB-1.
  • Cells transfected with FLAG-SOCS-6 were stimulated with 200 ng/mL IGF-1 and all samples were taken after 0, 5, 10, 20, 30, 60, 120, 180 and 300 mins of stimulation, respectively.
  • Cells transfected with FLAG- WSB-1 were stimulated with 200 ng/mL IGF-1 for 20 mins.
  • FLAG-SOCS-6 and FLAG-WSB-1 were immunoprecipitated with anti-FLAG antibodies and Western blotting was then carried out using an anti-phosphotyrosine Ab or an anti-phosophoMAP kinase Ab.
  • the anti- phosphotyrosine Ab blot was stripped and reprobed using an anti-FLAG Ab.
  • the anti- phosphoMAP kinase blot was stripped and reprobed using an anti-MAP kinase Ab.
  • the results shown in Figure 7 demonstrate tyrosine-phosphorylated proteins with SOCS-6 in response to IGF-1 stimulation.
  • 293T cells were left untransfected or were transiently transfected with either a FLAG epitope tagged version of SOCS-6 (S6) or a FLAG-tagged version of WSB-1.
  • Cells were left unstimulated (-) or were stimulated with 200 ng/mL IGF-1 (+).
  • FLAG-SOCS-6 and FLAG-WSB-1 were immunoprecipitated with anti-FLAG Abs.
  • non- transfected lysates were precipitated with the SOCS-6-SH2 domain, the SOCS-7-SH2 domain or control resin.
  • Western blotting was then carried out using an anti-ERS-4 Ab ( Figure 8a). The blot was stripped and reprobed using an anti-FLAG Ab ( Figure 8b).
  • Anti-p85 antibodies were used to test SOCS-6 association with this molecule in response to IGF-1 stimulation. The results are shown in Figure 9. The results show that in response to IGF-1 stimulation, SOCS-6 is capable of interacting with PI 3 kinase (p85) which is part of the IGF-1 signalling pathway.
  • the recombinant proteins were purified from bacterial cells lysed in 7 M guanidinium hydrochloride using immobilised nickel ion affinity chromatography. Purified proteins were refolded by dialysis into phosphate-buffered saline containing 0.02% w/v Tween-20, 0.5 mM tris(2-carboxyethyl)-phosphine. The refolded proteins were covalently immobilized onto NHS-activated Sepharose at a density of 3 mg of protein per mL of activated resin. "Control" resin was prepared by derivatizing NHS-activated Sepharose resin with ethanolamine.
  • phosphopeptide libraries were designed to probe the sequence specificity of the phosphopeptide-binding sites from the SH2 domains from SOCS-6 and SOCS-7. Two such libraries were synthesized, VE(pY)X ⁇ X 2 X 3 VHSGR and RN(pY)VF
  • TFA was removed by evaporation with a stream of nitrogen, the peptide library mixture was precipitated with di ethyl ether, solubilized in 50% v/v aqueous acetonitrile containing 0.1% v/v TFA, filtered and lyophilized.
  • the sequences of the synthetic libraries were confirmed by N-terminal sequencing and each degenerate position was found to contain an approximately equal proportion of each of the 19 different amino acids.
  • VEpYXXXVHSGR library screening 400 ⁇ L of immobilized protein resin was incubated with 4 mg of phosphopeptide library solubilized in 2 mL 50 mM sodium phosphate (pH 7.5) containing 150 mM NaCl, 2 mM DTT and 0.2% w/v Tween-20. The mixture was gently shaken at room temperature for 1 hour, then transferred to a disposable 10 mL chromatography column.
  • RNpYVFXXXLK library screening 180 ⁇ L of immobilized protein resin was incubated with 3.6 mg of phosphopeptide library solubilized in 1.8 mL 50 mM sodium phosphate (pH 7.5) containing 150 mM NaCl, 2 mM DTT and 0.2% w/v Tween-20. The mixture was gently shaken at room temperature for 1 hour, then transferred to a disposable 10 mL chromatography column. After allowing the peptide solution to drain, the resin was washed under gravity with 18 x 8 mL phosphate-buffered saline containing 0.2% w/v Tween-20 and 1 x 8 mL 2 mM sodium phosphate (pH 7.5).
  • This information can be used to predict possible SOCS-6 or SOCS-7 docking sites in naturally occurring tyrosine phosphorylated proteins.
  • possible -pTyr-Val- docking sites within the human insulin receptor substrate proteins occur at Y896 in ERS-1, Y823 in ERS-2 and Y700, Y828, Y921, Y959 and Y1046 in ERS-4.
  • the specificity information can also be used to design artificial phosphopeptide ligands which bind to the SH2 domains of SOCS-6 and SOCS-7. Such a peptide can then be used to set up an assay for screening the abililty of other peptide or non-peptide molecules to compete for binding to SOCS-6 or SOCS-7. Molecules identified in this way may act as antagonists of the biological activity of SOCS-6 and SOCS-7.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne, de manière générale, des molécules pouvant interagir avec des membres de la famille des protéines de suppression de la signalisation de cytokine (SOCS). Lesdites molécules vont des cibles protéiniques intracellulaires pour lesquelles la SOCS est un ligand, aux agents chimiques comprenant des entités protéiniques identifiées, entre autres, par criblage de produits naturels, de bibliothèques chimiques et/ou élaboration rationnelle de substances thérapeutiques. L'identification de cibles intracellulaires d'une protéine SOCS et/ou l'identification d'autres agents d'interaction de la molécule SOCS permet le développement d'une gamme d'applications thérapeutiques et diagnostiques. La présente invention concerne notamment la protéine SOCS-6 et son implication dans divers processus physiologiques tels que ceux induits par le facteur de croissance ou par la signalisation hormonale.
PCT/AU2002/001353 2001-10-05 2002-10-04 Molecules therapeutiques et diagnostiques pouvant interagir avec des proteines socs WO2003031468A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32738101P 2001-10-05 2001-10-05
US60/327,381 2001-10-05

Publications (1)

Publication Number Publication Date
WO2003031468A1 true WO2003031468A1 (fr) 2003-04-17

Family

ID=23276315

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2002/001353 WO2003031468A1 (fr) 2001-10-05 2002-10-04 Molecules therapeutiques et diagnostiques pouvant interagir avec des proteines socs

Country Status (1)

Country Link
WO (1) WO2003031468A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022030907A1 (fr) * 2020-08-07 2022-02-10 주식회사 에이엠메딕스 Composition destinée à améliorer ou traiter l'obésité comprenant le fragment polypeptidique du socs6

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066128A1 (fr) * 2000-03-09 2001-09-13 The Walter And Eliza Hall Institute Of Medical Research Procedes de regulation de la signalisation d'une cytokine
WO2002040543A1 (fr) * 2000-11-14 2002-05-23 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Fragment fonctionnel du recepteur de la leptine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066128A1 (fr) * 2000-03-09 2001-09-13 The Walter And Eliza Hall Institute Of Medical Research Procedes de regulation de la signalisation d'une cytokine
WO2002040543A1 (fr) * 2000-11-14 2002-05-23 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Fragment fonctionnel du recepteur de la leptine

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ALEXANDER W.S. ET AL.: "Suppressors of cytokine signaling (SOCS): negative regulators of signal transduction", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 66, October 1999 (1999-10-01), pages 588 - 592 *
DE SOUZA D. ET AL.: "SH2 domains from suppressor of cytokine signaling-3 and protein tyrosine phosphatase SHP-2 have similar binding specificities", BIOCHEMISTRY, vol. 41, 19 June 2002 (2002-06-19), pages 9229 - 9236 *
EYCKERMAN S. ET AL.: "Design and application of a cytokine-receptor-based interaction trap", NATURE CELL BIOLOGY, vol. 3, December 2001 (2001-12-01), pages 1114 - 1119 *
HILTON D.J. ET AL.: "SOCS proteins: Negative regulators of cytokine signal transduction", BLOOD, vol. 92, no. 10, SUPPL. 1, PART 1-2, 15 November 1998 (1998-11-15) - 8 December 1998 (1998-12-08), (40TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, MIAMI BEACH, FLORIDA, USA, 4-8 DECEMBER 1998), pages 476A *
KREBS D.L.: "SOCS-6 binds to insulin receptor substrate 4 and mice lacking the SOCS-6 gene exhibit mild growth retardation", MOLECULAR AND CELLULAR BIOLOGY, July 2002 (2002-07-01), pages 4567 - 4578 *
LOPACZYNSKI W.: "Differential regulation of signaling pathways for insulin and insulin-like growth factor I", ACTA BIOCHIMICA POLONICA, vol. 46, no. 1, 1999, pages 51 - 60 *
NICHOLSON S.E. ET AL.: "Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction", THE EMBO JOURNAL, vol. 18, no. 2, 1999, pages 375 - 385 *
NICHOLSON S.E. ET AL.: "The SOCS proteins: a new family of negative regulators of signal transduction", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 63, June 1998 (1998-06-01), pages 665 - 668 *
RAM P.A. ET AL.: "SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 50, 10 December 1999 (1999-12-10), pages 35553 - 35561 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022030907A1 (fr) * 2020-08-07 2022-02-10 주식회사 에이엠메딕스 Composition destinée à améliorer ou traiter l'obésité comprenant le fragment polypeptidique du socs6

Similar Documents

Publication Publication Date Title
US7288398B2 (en) Molecules
US6414128B1 (en) Haemopoietin receptor and genetic sequences encoding same
US20080009444A1 (en) Biologically active complex of NR6 and cardiotrophin-like-cytokine
US20100199368A1 (en) Bcl-2-modifying factor (bmf) sequences and their use in modulating apoptosis
US6613745B1 (en) Therapeutic molecules derived from snake venom
US20090143571A1 (en) Novel genes and their use in the modulation of obesity, diabetes and energy imbalance
US7166698B2 (en) Mammalian gene, bcl-w, belongs to the bcl-2 family of apoptosis-controlling genes
WO1998053061A9 (fr) Nouveaux genes codant une proteine a doigt de zinc, un facteur d'echange de nucleotides guaniniques, une proteine du stress ou une proteine de liaison du stress
US20080274973A1 (en) novel haemopoietin receptor and genetic sequences encoding same
US20070065915A1 (en) Nucleic acid expressed in the hypothalamus or muscle tissue in obese animals
US20060194233A1 (en) Ligand of the protein "beacon"
WO2003033513A1 (fr) Genes exprimes de maniere differentielle, associes a l'obesite et au diabete de type 2
WO2003031468A1 (fr) Molecules therapeutiques et diagnostiques pouvant interagir avec des proteines socs
US20040214188A1 (en) Gene and uses therefor
US7192576B1 (en) Biologically active complex of NR6 and cardiotrophin-like-cytokine
AU2002304971B2 (en) Bcl-2-modifying factor (Bmf) sequences and their use in modulating apoptosis
WO2002100416A1 (fr) Molecules socs-5, leur criblage et leurs utilisations therapeutiques
WO2000006720A1 (fr) Nouvelle molecule regulatoire et sequences genetiques codant pour celles-ci
WO2003016542A1 (fr) Genes lies a l'obesite exprimes au moins dans l'hypothalamus
AU2002304971A1 (en) Bcl-2-modifying factor (Bmf) sequences and their use in modulating apoptosis
AU2002308412A1 (en) A gene and uses therefor
AU2002227795A1 (en) Nucleic acid expressed in the hypothalamus or muscle tissue in obese animals
AU2002332956A1 (en) Differentially expressed genes associated with obesity and type 2 diabetes
AU5140899A (en) A novel regulatory molecule and genetic sequences encoding same
WO2004037857A1 (fr) Proteines bfk comme molecules therapeutiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP